ES-FSG-FO-00218-WD

Abstract 2
First- & second-generation EGFR TKIs 3
Third-generation EGFR TKIs in patients with acquired resistance 5
Third-generation EGFR TKIs as first-line treatment 7
Factors influencing first-line treatment choice: mechanisms of resistance & subsequent therapy options 7
Factors influencing first-line treatment choice: brain metastases 9
Factors influencing first-line treatment choice: tolerability profile 10
Future perspective 12
Executive summary 13
References 14

RkJQdWJsaXNoZXIy MzQyNTUz